Shares of Stemline Therapeutics Inc. (NASDAQ:STML) dropped 1.5% on Monday . The stock traded as low as $7.87 and last traded at $8.03, with a volume of 67,700 shares trading hands. The stock had previously closed at $8.15.

STML has been the topic of several analyst reports. Roth Capital reaffirmed a “buy” rating and issued a $32.00 target price on shares of Stemline Therapeutics in a report on Thursday, August 25th. Jefferies Group reaffirmed a “buy” rating and issued a $23.00 target price on shares of Stemline Therapeutics in a report on Friday, July 22nd. Wedbush reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Stemline Therapeutics in a report on Tuesday, August 23rd. Finally, Zacks Investment Research raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a report on Wednesday, July 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Stemline Therapeutics currently has an average rating of “Buy” and a consensus target price of $19.31.

The company has a 50 day moving average price of $7.57 and a 200-day moving average price of $6.32. The company’s market cap is $143.13 million.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.03. On average, analysts forecast that Stemline Therapeutics Inc. will post ($2.11) EPS for the current year.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.